Assembly of High-Potency Photosensitizer-Antibody Conjugates through Application of Dendron Multiplier Technology

resumo

Exploitation of photosensitizers as payloads for antibody-based anticancer therapeutics offers a novel alternative to the small pool of commonly utilized cytotoxins. However, existing bioconjugation methodologies are incompatible with the requirement of increased antibody loading without compromising antibody function, stability, or homogeneity. Herein, we describe the first application of dendritic multiplier groups to allow the loading of more than 4 porphyrins to a full IgG antibody in a site-specific and highly homogeneous manner. Photophysical evaluation of UV-visible absorbance and singlet oxygen quantum yields highlighted porphyrin-dendron 14 as the best candidate for bioconjugation; with subsequent bioconjugation producing a HER2-targeted therapeutic with average loading ratios of 15.4:1. In vitro evaluation of conjugate 18 demonstrated a nanomolar photocytotoxic effect in a target cell line, which overexpresses HER2, with no observed photocytotoxicity at the same concentration in a control cell line which expresses native HER2 levels, or in the absence of irradiation with visible light.

palavras-chave

PHOTODYNAMIC THERAPY; CLICK CHEMISTRY; NEXT-GENERATION; STABILITY; MILD; PHTHALOCYANINE; PORPHYRINS; STRATEGIES; ADCS

categoria

Biochemistry & Molecular Biology; Chemistry

autores

Bryden, F; Maruani, A; Rodrigues, JMM; Cheng, MHY; Savoie, H; Beeby, A; Chudasama, V; Boyle, RW

nossos autores

Partilhe este projeto

Publicações similares

Usamos cookies para atividades de marketing e para lhe oferecer uma melhor experiência de navegação. Ao clicar em “Aceitar Cookies” você concorda com nossa política de cookies. Leia sobre como usamos cookies clicando em "Política de Privacidade e Cookies".